In a study in China, 21 patients with severe/critical COVID‐19 received intravenous TCZ (4–8 mg/kg) and demonstrated improved oxygenation, reduced CRP concentrations, decreased inflammation, rapid recovery, and minimal side effects, along with good clinical benefit and therapeutic potential.319. Here, CRP is linked to COVID-19.